Twitxy Saved

Alltrna

@alltrna

Alltrna is the world’s first transfer RNA (tRNA) platform company, and we are unlocking the vast therapeutic potential within #tRNA biology.
Cambridge, Massachusetts alltrna.com Joined September 2021
182 Following 740 Followers 421 Posts

Latest posts 5

Alltrna @alltrna
At CSHL Translational Control, Alltrna scientist Jalyce Heller shared our research on engineering tRNAs to address disease-causing premature stop codons.

tRNAs play an essential role in turning genetic instructions into proteins. When a premature stop codon interrupts those instructions, the cell can stop making a protein before it is complete.

Our approach is to engineer tRNAs that recognize these stop codons, insert the intended amino acid, and allow protein production to continue.

Jalyce’s work contributes to our understanding of how engineered tRNAs can be developed as medicines for #StopCodonDisease, including the potential to address the same underlying mutation across different genes and diseases.

Learn more about tRNA biology and our approach: alltrna.com/trna-biology
Alltrna @alltrna
At RNA Leaders USA, Alltrna CSO Dave Hava will share how preclinical work with AP003 is informing a mutation-defined clinical development strategy for Stop Codon Disease.

AP003 is engineered to read through the Arg-TGA premature stop codon. In preclinical models of PKU and MMA, the same tRNA therapeutic restored the distinct full-length proteins disrupted in each disease.

These findings support the potential to bring patients with different rare diseases into a common development program when they share the same underlying mutation, an approach that could help make development more feasible across rare and ultra-rare patient populations.

Join Dave on Sept. 25 at 11:20am ET for “Advancing tRNA Therapeutics for Stop Codon Disease: Preclinical Data Supporting a Basket Clinical Development Strategy.”

Learn more: informaconnect.com/rna-leaders-us…
Alltrna @alltrna
We’re looking forward to joining the tRNA community for the 30th tRNA Conference at a time when the therapeutic potential of tRNA is beginning to be explored in the clinic.

Alltrna will share our work on premature stop codon readthrough, including the science supporting AP003, now being evaluated in the first clinical trial of a tRNA therapeutic. Bringing AP003 to this development stage has required work across tRNA biology, engineering, chemical modification, delivery, and manufacturing.

The tRNA Conference has long been an important forum for bringing this scientific community together. We’re pleased to present at this year’s meeting and look forward to learning from colleagues across the field while sharing what we’ve learned along the way.

Learn more about our lead program: alltrna.com/trna-medicines…